ALK-Abelló A/S (AKBLF)

USD 21.35

(-4.47%)

Market Cap (In USD)

4.75 Billion

Revenue (In USD)

4.82 Billion

Net Income (In USD)

486 Million

Avg. Volume

8.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13.25-27.0328
PE
39.54
EPS
0.54
Beta Value
0.613
ISIN
DK0061802139
CUSIP
-
CIK
-
Shares
222611053.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter Halling
Employee Count
-
Website
https://www.alk.net
Ipo Date
2009-11-16
Details
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.